logo

Slide Shows

Share
Events

Biotech Stocks Facing FDA Decision In April 2021 Four novel drugs were approved by the FDA in March taking the tally of new drug approvals in the first quarter of this year to 14. This compares with 11 new drug approvals in the first quarter of 2020. In all, a total of 53 novel drugs were approved last year.

New Drugs Approved In December Let us take a look at the new drugs approved in the month of December 2020.

Biotech Stocks Facing FDA Decision In January 2021 As 2020 draws to a close, it’s time to take a look back at some of the regulatory news that made headlines in December and look ahead at what’s in store for January 2021.

New Drugs Approved In November The Food and Drug Administration approved 6 new drugs last month. This compares with 12 new drugs approved in November last year. Now, let us take a look at the new drugs approved in the month of November.

Biotech Stocks Facing FDA Decision In December 2020 So far, 46 *novel drugs have secured the official stamp of FDA approval compared to 41 during the same period 2019. *Novel drugs are new molecular entities (NMEs) having chemical structures that have never been approved before. Let's take a look at the biotech stocks awaiting FDA decision in December.

Biotech Stocks Facing FDA Decision In November 2020 As of this writing, the FDA has approved 42 novel drugs so far this year compared to 33 during the same period (Jan – Oct) last year. Let’s take a look at the companies that await a ruling from the FDA in November.

New Drugs Approved In September Let us take a look at the new drugs approved in the month of September.

Biotech Stocks Facing FDA Decision In October 2020 Let’s take a look at the companies that await a ruling from the FDA in October.

New Drugs Approved In August The Food and Drug Administration approved 11 new drugs in August, compared with 8 drugs approved in the same period last year. Let us take a look at the new drugs approved in the month of August.

Biotech Stocks Facing FDA Decision In September So far this year, 36 novel drugs have passed muster with the FDA compared to 26 during the same period (Jan- Aug) in 2019. Let’s take a look at the companies that await a ruling from the FDA next month.